146 related articles for article (PubMed ID: 13679859)
21. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
El-Khoury V; Breuzard G; Fourré N; Dufer J
Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
[TBL] [Abstract][Full Text] [Related]
23. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y.
Hirose T; Sowa Y; Takahashi S; Saito S; Yasuda C; Shindo N; Furuichi K; Sakai T
Oncogene; 2003 Oct; 22(49):7762-73. PubMed ID: 14586402
[TBL] [Abstract][Full Text] [Related]
24. Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.
Noh EJ; Jang ER; Jeong G; Lee YM; Min CK; Lee JS
Cancer Res; 2005 Dec; 65(24):11400-10. PubMed ID: 16357148
[TBL] [Abstract][Full Text] [Related]
25. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
[TBL] [Abstract][Full Text] [Related]
26. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Qi H; Ratnam M
Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of RhoB loss of expression in lung cancer.
Mazières J; Tovar D; He B; Nieto-Acosta J; Marty-Detraves C; Clanet C; Pradines A; Jablons D; Favre G
BMC Cancer; 2007 Nov; 7():220. PubMed ID: 18047684
[TBL] [Abstract][Full Text] [Related]
28. CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A.
Kang JH; Kim MJ; Chang SY; Sim SS; Kim MS; Jo YH
J Cell Biochem; 2008 Jul; 104(4):1192-203. PubMed ID: 18275041
[TBL] [Abstract][Full Text] [Related]
29. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
30. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
32. Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression.
Matsuoka H; Fujimura T; Hayashi M; Matsuda K; Ishii Y; Aramori I; Mutoh S
Biochem Pharmacol; 2007 Aug; 74(3):465-76. PubMed ID: 17559812
[TBL] [Abstract][Full Text] [Related]
33. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
34. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
35. Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Zhou J; Hernandez G; Tu SW; Scholes J; Chen H; Tseng CP; Hsieh JT
Cancer Res; 2005 Jul; 65(14):6089-96. PubMed ID: 16024609
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
37. Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway.
Kim YH; Lim JH; Lee TJ; Park JW; Kwon TK
J Cell Biochem; 2007 Jul; 101(4):987-95. PubMed ID: 17407153
[TBL] [Abstract][Full Text] [Related]
38. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis.
Zhang Y; Adachi M; Kawamura R; Imai K
Cell Death Differ; 2006 Jan; 13(1):129-40. PubMed ID: 15947789
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2.
Choi J; Choi K; Benveniste EN; Rho SB; Hong YS; Lee JH; Kim J; Park K
Cancer Res; 2005 Jul; 65(13):5554-60. PubMed ID: 15994927
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
Mukhopadhyay NK; Weisberg E; Gilchrist D; Bueno R; Sugarbaker DJ; Jaklitsch MT
Ann Thorac Surg; 2006 Mar; 81(3):1034-42. PubMed ID: 16488717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
